Document is current

Article History

Received: 8 February 2024

Accepted: 16 November 2024

First Online: 18 December 2024

Declarations

:

: The DELIVER study was conducted in accordance with standards of Good Clinical Practice as defined by the International Conference on Harmonisation and all applicable federal and local regulations. The local review board or a central institutional review board/ethics committee approved all study documentation at each of the 96 study sites. All patients provided written informed consent prior to study participation. DELIVER is registered on ClinicalTrials.gov (NCT04418765) and EudraCT (2019-004497-25).

: Not applicable.

: PB reports, over the last 36 months, travel grants, honoraria for advisory boards, speaker panels or clinical investigation studies from Alder, Allergan, Angelini, Assosalute, Bayer, electroCore, Eli Lilly, GSK, Lundbeck, Lusofarmaco, 1MED, MSD, New Penta, Noema Pharma, Novartis, Stx-Med, Teva, Visufarma, and Zambon. SFA, SAR, and XYL are employees of H. Lundbeck A/S, Copenhagen, Denmark. HRE was an employee of Clinigma, Copenhagen, Denmark, at the time the exit interviews were conducted. PJG reports, over the last 36 months, a grant from Celgene, and personal fees from Aeon Biopharma, Allergan/AbbVie, CoolTech LLC, Dr. Reddy’s, Eli Lilly, Epalex, Impel Neuropharma, Lundbeck, Novartis, Pfizer, Praxis, Sanofi, Satsuma, Teva, and Tremeau. He also reports personal fees for advice through Gerson Lehrman Group, Guidepoint, SAI Med Partners, and Vector Metric; fees for educational materials from CME Outfitters and WebMD; publishing royalties or fees from Massachusetts Medical Society, Oxford University Press, UpToDate, and Wolters Kluwer; fees for medicolegal advice in headache; and a patent for magnetic stimulation for headache (No. WO2016090333 A1) assigned to eNeura without fee.